## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.1% below STRENGTH zone (3.0-6.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($134.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. ICU Medical: Difficult Transition, A More Interesting Company (Upgrade) (NASDAQ:ICUI)**
- Source: Seeking Alpha | 20251230T220948 | Bullish | Relevance: 100%
- ICU Medical has transitioned from a difficult integration period towards focusing on growth and margin expansion, notably by divesting its low-margin IV solutions business and launching new products. This strategic shift is expected to improve gross margins to 43-45%, achieve sustained EBITDA margins over 20%, and support double-digit free cash flow growth for deleveraging. Despite low growth, the company's valuation based on discounted cash flow and margin leverage suggests a fair value in the $180s, making it an attractive option among small med-tech companies.

**2. ICU Medical IV Gravity Burette Removal For Missing Internal Shut-Off**
- Source: U.S. Food and Drug Administration (.gov) | 20251230T040948 | Bearish | Relevance: 100%
- ICU Medical is recalling certain IV Gravity Burette Sets because they are missing an internal shut-off valve, which could lead to serious adverse health consequences including injury or death. The FDA has identified this as the most serious type of recall. Customers are advised to stop using affected products immediately, identify, and destroy or quarantine them.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 17.8x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 17.8 |
| Current P/E | 18.9 |
| YoY Growth | 6.0% |
| EPS Direction | RISING |

### Technicals

MRS_10 stable at -2.1% (minimal 5-day change). Below STRENGTH zone by 5.1pp (needs >3.0% for momentum thesis). Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.95), momentum weakening. RSI neutral at 47. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.10% (CS: 12) | Weak |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | -0.95 | Bearish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.075x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $142.67
- **Stop Loss:** $134.61 (5.6% risk)
- **Target:** $150.73 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 178
- **Position Value:** $25,395.26
- **Portfolio %:** 25.40%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*